June 29th 2025
Results from Invivyd’s pemivibart (Pemgarda) phase 3 trial show it had a significant PrEP effect during the 6-month on-drug period for both immunocompromised and immunocompetent populations.
Vaccine Experts Weigh in on Trump's Possible RFK Appointment
January 13th 2017In light of recent news that reported “vaccine skeptic,” Robert F. Kennedy, may be appointed to lead president-elect Donald Trump’s panel on vaccine safety, Contagion spoke with vaccine experts to learn of any potential ramifications this may have.
Read More
Real-Time Patient-Centered Research Needed to Improve Outbreak Response
January 9th 2017A new report finds that real-time patient-centered research is possible during an outbreak, and indeed, necessary to strengthen systems, improve surveillance and response, and create better diagnostics, therapeutics and vaccines.
Read More
New Global Coalition Aims to Stop Future Epidemics with New Vaccines
January 3rd 2017A new coalition created by the Bill & Melinda Gates Foundation and other global partners will launch at this year’s World Economic Forum, with the goal of supporting the fast-tracked development of new vaccines.
Read More